These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 38415920)
21. Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis. Smith M; Ryan KJ; Gutierrez H; Sanchez LHG; Anderson JN; Acosta EP; Benner KW; Guimbellot JS J Cyst Fibros; 2022 Jan; 21(1):e8-e10. PubMed ID: 34130909 [TBL] [Abstract][Full Text] [Related]
22. Efficacy of Elexacaftor-Tezacaftor-Ivacaftor on chronic rhinosinusitis in cystic fibrosis. Di Gioia S; Lucca F; Venditto L; Sandri G; Tommasi N; Cipolli M; Molteni G Am J Otolaryngol; 2024; 45(3):104236. PubMed ID: 38417261 [TBL] [Abstract][Full Text] [Related]
23. Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in a man with A559T and 3120+1G>CFTR variants. Mitchell E; Albon D Pediatr Pulmonol; 2024 Jul; 59(7):2009-2011. PubMed ID: 38607232 [No Abstract] [Full Text] [Related]
24. Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years - The RECOVER study. Mainz JG; Lester K; Elnazir B; Williamson M; McKone E; Cox D; Linnane B; Zagoya C; Duckstein F; Barucha A; Davies JC; McNally P; J Cyst Fibros; 2024 May; 23(3):474-480. PubMed ID: 37806792 [TBL] [Abstract][Full Text] [Related]
25. Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype. Carnovale V; Iacotucci P; Terlizzi V; Colangelo C; Medio P; Ferrillo L; De Gregorio F; Francalanci M; Taccetti G; Buonaurio S; d'Ippolito M; Marsicovetere G; D'Andria M; Ferrara N; Salvatore D Respir Med; 2021; 189():106646. PubMed ID: 34673344 [TBL] [Abstract][Full Text] [Related]
26. Predicting weight gain in patients with cystic fibrosis on triple combination modulator. Stewart KL; Szczesniak R; Liou TG Pediatr Pulmonol; 2024 Jun; 59(6):1724-1730. PubMed ID: 38607242 [TBL] [Abstract][Full Text] [Related]
27. Elexacaftor/Tezacaftor/Ivacaftor Effectiveness in N1303K Variant in Adult People With Cystic Fibrosis. Gonçalves Martynychen Canan M; Souza Sokoloski C; Rossetti Severo C; Zahi Rached S; Abensur Athanazio R Arch Bronconeumol; 2024 Aug; 60(8):526-528. PubMed ID: 38714384 [No Abstract] [Full Text] [Related]
28. Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. Burgel PR; Durieu I; Chiron R; Ramel S; Danner-Boucher I; Prevotat A; Grenet D; Marguet C; Reynaud-Gaubert M; Macey J; Mely L; Fanton A; Quetant S; Lemonnier L; Paillasseur JL; Da Silva J; Martin C; Am J Respir Crit Care Med; 2021 Jul; 204(1):64-73. PubMed ID: 33600738 [No Abstract] [Full Text] [Related]
29. Short-term effect of elexacaftor-tezacaftor-ivacaftor on lung function and transplant planning in cystic fibrosis patients with advanced lung disease. B B; A R; G R; A N; D G; S G; P F; M SG; L C; B G J Cyst Fibros; 2021 Sep; 20(5):768-771. PubMed ID: 34162524 [No Abstract] [Full Text] [Related]
30. Elexacaftor/tezacaftor/ivacaftor (Trikafta) for cystic fibrosis. Med Lett Drugs Ther; 2020 Jan; 62(1589):5-7. PubMed ID: 31999662 [No Abstract] [Full Text] [Related]
31. Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. Wang A; Lee M; Keller A; Jian S; Lowe K; Finklea JD; Jain R J Cyst Fibros; 2024 Jan; 23(1):91-98. PubMed ID: 37244841 [TBL] [Abstract][Full Text] [Related]
32. Immunosuppressant management upon elexacaftor/tezacaftor/ivacaftor initiation in cystic fibrosis patients with prior liver transplant. Coman D; Vincent C; Huard G; Marleau D; Lavoie A; Hercun J J Cyst Fibros; 2024 May; 23(3):561-562. PubMed ID: 38000917 [No Abstract] [Full Text] [Related]
34. Depression Symptoms in Patients with Cystic Fibrosis Fluctuate at Baseline and Improve with Elexacaftor/Tezacaftor/Ivacaftor Therapy. Piehler L; Thalemann R; Lehmann C; Stahl M; Mall MA; Graeber SY Am J Respir Crit Care Med; 2024 Aug; 210(3):365-367. PubMed ID: 38843542 [No Abstract] [Full Text] [Related]
35. Reply to Piehler Duff AJA; Lee TWR Am J Respir Crit Care Med; 2024 Aug; 210(3):367. PubMed ID: 38843537 [No Abstract] [Full Text] [Related]
36. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC; Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620 [TBL] [Abstract][Full Text] [Related]
37. Elexacaftor-tezacaftor-ivacaftor decreases pseudomonas abundance in the sinonasal microbiome in cystic fibrosis. Zemke AC; Hilliam Y; Stapleton AL; Kimple AJ; Goralski JL; Shaffer AD; Pilewski JM; Senior BA; Lee SE; Cooper VS Int Forum Allergy Rhinol; 2024 May; 14(5):928-938. PubMed ID: 37837613 [TBL] [Abstract][Full Text] [Related]
38. Year in review 2023 - Back to the future. Cristiani L; Fernandes FF J Cyst Fibros; 2024 Mar; 23(2):203-207. PubMed ID: 38431442 [TBL] [Abstract][Full Text] [Related]
39. PREFUL MRI for Monitoring Perfusion and Ventilation Changes after Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis: A Feasibility Study. Dohna M; Voskrebenzev A; Klimeš F; Kaireit TF; Glandorf J; Pallenberg ST; Ringshausen FC; Hansen G; Renz DM; Wacker F; Dittrich AM; Vogel-Claussen J Radiol Cardiothorac Imaging; 2024 Apr; 6(2):e230104. PubMed ID: 38573129 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS; Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]